Treatment with peginterferon alfa-2a alone produces significantly higher sustained virologic responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) ...

A clinical study led by Dr. Jordan Feld, a liver specialist at Toronto Centre for Liver Disease, University Health Network (UHN), showed an experimental antiviral drug can significantly speed up ...

Chronic infection with hepatitis B virus and hepatitis delta virus (HDV) results in the most severe form of viral hepatitis. There is no currently approved treatment. We investigated the safety and ...

San Diego, California — One-year results from the phase 3 ADVANCE study suggests that peginterferon-β1a (Plegridy, Biogen Idec) has the potential to offer the efficacy and safety of currently ...

PALO ALTO, Calif., Aug. 20, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, ...

Biogen Idec today announced positive topline results from a phase 3 trial of peginterferon beta-1a in relapsing-remitting multiple sclerosis (RRMS). The treatment is a pegylated version of interferon ...

Peginterferon alfa-2a (Pegasys, Roche Products) has a UK marketing authorisation for 'the treatment of chronic hepatitis C in adult patients who are positive for serum HCV-RNA, including patients with ...

The combination of bulevirtide plus peginterferon alfa-2a is superior to bulevirtide monotherapy for achieving undetectable hepatitis D virus (HDV) RNA level at 24 weeks after the end of treatment in ...

Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine.

What is peginterferon alfa 2a? Peginterferon alfa 2a is an immunotherapy drug. Peginterferon alfa 2a is a possible treatment for some types of blood cancers called myeloproliferative neoplasms (MPNs).